Victoria's Secret (VSCO) Proxy Clash: What Does Rejecting Brett Blundy Signal About Board Strategy?

Victoria's Secret & Company

Victoria's Secret & Company

VSCO

0.00

  • In early May 2026, Victoria’s Secret & Co. disclosed that activist investor BBRC International launched a proxy contest urging shareholders to withhold votes from two board nominees and oppose executive pay, while the company’s board defended its record, rejected BBRC Chairman Brett Blundy as a director candidate over multiple risk concerns, and confirmed its short-term rights plan will lapse on May 18, 2026.
  • The board highlighted a very large total shareholder return since appointing CEO Hillary Super in late 2024 and pointed to extensive, but ultimately unsuccessful, attempts to collaborate with BBRC that did not include Blundy’s personal appointment, underscoring a sharp governance divide even as the company reiterates its commitment to shareholder engagement.
  • We’ll now examine how this escalating proxy contest and the board’s rejection of Brett Blundy as a director could influence Victoria’s Secret’s investment narrative.

Find 51 companies with promising cash flow potential yet trading below their fair value.

Victoria's Secret Investment Narrative Recap

To own Victoria’s Secret today, you need to believe the brand refresh, omnichannel push, and supply chain work can translate into durable earnings, despite tariff pressure, mall exposure, and intense competition. The BBRC proxy fight and the board’s rejection of Brett Blundy add governance noise but do not obviously change near term trading catalysts, which still center on executing 2026 guidance and protecting margins as promotions, tariffs, and inventory discipline all pull in different directions.

The most relevant recent announcement here is the board’s May 5 update on BBRC’s proxy contest, which stressed board independence, rejected Blundy over multiple risk concerns, and highlighted a 164% total shareholder return since Hillary Super became CEO in late 2024. That same update confirmed the short term rights plan will expire on May 18, 2026, a move that may reassure some investors while keeping attention firmly on governance and executive pay ahead of the June 11 annual meeting.

Yet investors should also weigh how the added governance friction could interact with already thin net margins and high debt levels if...

Victoria's Secret's narrative projects $7.6 billion revenue and $487.1 million earnings by 2029. This requires 4.9% yearly revenue growth and a $326.1 million earnings increase from $161.0 million today.

Uncover how Victoria's Secret's forecasts yield a $65.56 fair value, a 38% upside to its current price.

Exploring Other Perspectives

VSCO 1-Year Stock Price Chart
VSCO 1-Year Stock Price Chart

Some of the most optimistic analysts were expecting revenue of about US$7.7 billion and earnings near US$427 million by 2029, but if you worry that cutting promotions could crimp sales in a heated proxy fight, it shows how sharply views can differ and why both the bullish and more cautious scenarios may need a fresh look after this news.

Explore 4 other fair value estimates on Victoria's Secret - why the stock might be worth 14% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your Victoria's Secret research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
  • Our free Victoria's Secret research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Victoria's Secret's overall financial health at a glance.

Seeking Other Investments?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

  • The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
  • AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
  • Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.